You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
AstraZeneca
Merck
Express Scripts

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

DESVENLAFAXINE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for desvenlafaxine and what is the scope of patent protection?

Desvenlafaxine is the generic ingredient in four branded drugs marketed by Alembic Pharms Ltd, Osmotica Pharm Corp, Sun Pharma Global, Teva Pharms Usa, Actavis Labs Fl, Casi Pharms Inc, Hikma, Intellipharmaceutics, Lupin Ltd, Mylan, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in fifteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for desvenlafaxine. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for DESVENLAFAXINE

See drug prices for DESVENLAFAXINE

Recent Clinical Trials for DESVENLAFAXINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
H. Lundbeck A/SPhase 4
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Luye Pharma Group Ltd.Phase 1

See all DESVENLAFAXINE clinical trials

Generic filers with tentative approvals for DESVENLAFAXINE
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial50MGTABLET, EXTENDED RELEASE;ORAL
  Start Trial  Start Trial100MGTABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for DESVENLAFAXINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial   Start Trial
Lupin Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204172-001 Jun 29, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Yichang Humanwell DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 210014-002 Oct 1, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
Casi Pharms Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204028-001 Jun 29, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharma Global DESVENLAFAXINE desvenlafaxine fumarate TABLET, EXTENDED RELEASE;ORAL 205583-001 Jan 28, 2014 DISCN Yes No   Start Trial   Start Trial   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
Colorcon
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.